Skip to main content
OpenTrials
Completed

NCT Number: NCT04773353

Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian Women

To demonstrate non-inferiority of FE 999049 compared with GONAL-F with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

21 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Ferring Investigational Site, Ahmedabad, Gujarat, India

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed Consent Forms signed prior to screening evaluations.
  • In good physical and mental health as judged by the investigator.
  • Indian (i.e., possessing an Indian identification card and having native Indian parents) pre-menopausal females between the ages of 21 and 40 years. The participants must be at least 21 years (including the 21st birthday) when they sign the informed consent and no more than 40 years (up to the day before the 41st birthday) at the time of randomization.
  • Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II (defined by the revised American Society for Reproductive Medicine [ASRM] classification, 1996) or with partners diagnosed with male factor infertility, eligible for in vitro fertilization (IVF) and/or ICSI using fresh or frozen ejaculated sperm from male partner or sperm donor.
  • Infertility for at least one year before randomization for participants <35 years or for at least 6 months for participants ≥35 years (not applicable in case of tubal or severe male factor infertility).
  • The trial cycle will be the participant's first controlled ovarian stimulation cycle for IVF/ICSI.
  • Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory.
  • Hysterosalpingography, hysteroscopy, saline infusion sonography, or transvaginal ultrasound documenting a uterus consistent with expected normal function (e.g. no evidence of clinically interfering uterine fibroids defined as submucous or intramural fibroids larger than 3 cm in diameter, no polyps and no congenital structural abnormalities which are associated with a reduced chance of pregnancy) within 1 year prior to randomization.
  • Transvaginal ultrasound documenting presence and adequate visualization of both ovaries, without evidence of significant abnormality (e.g., enlarged ovaries which would contraindicate the use of gonadotropins) and normal adnexa (e.g., no hydrosalpinx) within 1 year prior to randomization. Both ovaries must be accessible for oocyte retrieval.
  • Early follicular phase (cycle day 2-4) serum levels of FSH between 1 and 15 IU/L (results obtained within 3 months prior to randomization).
  • Negative serum Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) antibody tests within 1 year prior to randomization.
  • Body mass index (BMI) between 17.5 and 32.0 kg/m^2 (both inclusive) at screening.
  • Willing to accept transfer of 1-2 embryos.

Exclusion criteria

  • Known endometriosis stage III-IV (defined by the revised ASRM classification, 1996).
  • One or more follicles ≥10 mm (including cysts) observed on the transvaginal ultrasound prior to randomization on stimulation day 1 (puncture of cysts is allowed prior to randomization).
  • Known history of recurrent miscarriage (defined as three consecutive losses after ultrasound confirmation of pregnancy [excluding ectopic pregnancy] and before Week 24 of pregnancy).
  • Known abnormal karyotype of participant or of her partner/sperm donor, as applicable, depending on source of sperm used for insemination in this trial.
  • Any known clinically significant systemic disease (e.g., insulin-dependent diabetes).
  • Known inherited or acquired thrombophilia disease.
  • Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
  • Known porphyria.
  • Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) with the exception of controlled thyroid function disease.
  • Known presence of anti-FSH antibodies (based on the information available in the participant's medical records).
  • Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus which would contraindicate the use of gonadotropins.
  • Known moderate or severe impairment of renal or hepatic function.
  • Any abnormal finding of clinical chemistry, haematology or vital signs at screening which is clinically significant as judged by the investigator.
  • Currently breast-feeding.
  • Undiagnosed vaginal bleeding.
  • Known abnormal cervical cytology of clinical significance observed within 3 years prior to randomization (unless the clinical significance has been resolved).
  • Findings at the gynecological examination at screening which preclude gonadotropin stimulation or are associated with a reduced chance of pregnancy, e.g., congenital uterine abnormalities or retained intrauterine device.
  • Pregnancy (negative urinary pregnancy tests must be documented at screening and prior to randomization) or contraindication to pregnancy.
  • Known current active pelvic inflammatory disease.
  • Use of fertility modifiers during the last menstrual cycle before randomization, including dehydroepiandrosterone (DHEA), metformin or cycle programming with oral contraceptives, progestogen or estrogen preparations.
  • Use of hormonal preparations (except for thyroid medication) during the last menstrual cycle before randomization.
  • Known history of chemotherapy (except for gestational conditions) or radiotherapy.
  • Current or past (1 year prior to randomization) abuse of alcohol or drugs.
  • Current (last month) intake of more than 14 units of alcohol per week.
  • Current or past (3 months prior to randomization) smoking habit of more than 10 cigarettes per day.
  • Hypersensitivity to any active ingredient or excipients in the medicinal products used in the trial.
  • Previous participation in the trial.
  • Use of any non-registered investigational drugs during the last 3 months prior to randomization.

Treatment and study plan

Follitropin Delta (FE 999049)

Drug

FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (<15 pmol/L) the daily FE 999049 dose was 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose was on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose was fixed throughout the stimulation period and maximum allowed daily dose was 12 μg. Participants could be treated for a maximum of 20 days.

Other names: REKOVELLE

Follitropin Alfa (GONAL-F)

Drug

GONAL-F was administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 450 IU. Participants could be treated for a maximum of 20 days.

Other names: GONAL-F

Primary outcomes

  1. Ongoing pregnancy rate

    Time frame: 10-11 weeks after embryo transfer

    Ongoing pregnancy is defined as at least one intrauterine viable fetus 10-11 weeks after embryo transfer.

Secondary outcomes

  1. Positive beta human chorionic gonadotropin (βhCG) rate

    Time frame: 13-15 days after embryo transfer

    Positive βhCG is defined as positive serum βhCG test 13-15 days after embryo transfer.

  2. Clinical pregnancy rate

    Time frame: 5-6 weeks after embryo transfer

    Clinical pregnancy is defined as at least one gestational sac 5-6 weeks after embryo transfer.

  3. Vital pregnancy rate

    Time frame: 5-6 weeks after embryo transfer

    Vital pregnancy is defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after embryo transfer.

  4. Implantation rate

    Time frame: 5-6 weeks after embryo transfer

    Implantation rate is defined as the number of gestational sacs 5-6 weeks after transfer divided by number of embryos transferred.

  5. Ongoing implantation rate

    Time frame: 10-11 weeks after embryo transfer

    Ongoing implantation rate is defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of embryos transferred.

  6. Proportion of subjects with extreme ovarian responses

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

    Extreme ovarian response is defined as <4, ≥15 or ≥20 oocytes retrieved.

  7. Proportion of subjects with early ovarian hyperstimulation syndrome (OHSS) (including OHSS of moderate/severe grade) and/or preventive interventions for early OHSS

    Time frame: ≤9 days after triggering of final follicular maturation

    The proportion of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS will be presented.

  8. Proportion of subjects with cycle cancellation due to poor or excessive ovarian response or embryo transfer cancellation due to excessive ovarian response / OHSS risk

    Time frame: At end-of-stimulation (up to 20 stimulation days) or transfer visit

    The proportion of participants with cycle cancellation due to poor or excessive ovarian response or embryo transfer cancellation due to excessive ovarian response / OHSS risk will be presented.

  9. Number of follicles on stimulation Day 6

    Time frame: On stimulation Day 6

    Counted by ultrasound for the right and left ovary.

  10. Number of follicles at end-of-stimulation

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    Counted by ultrasound for the right and left ovary.

  11. Size of follicles on stimulation Day 6

    Time frame: On stimulation Day 6

    Measured by ultrasound for the right and left ovary.

  12. Size of follicles at end-of-stimulation

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    Measured by ultrasound for the right and left ovary.

  13. Number of oocytes retrieved

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

    The number of oocytes retrieved will be recorded at the oocyte retrieval visit.

  14. Proportion of subjects with <4, 4-7, 8-14, 15-19 and ≥20 oocytes retrieved

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

  15. Percentage of metaphase II oocytes (only applicable for those inseminated using intracytoplasmic sperm injection [ICSI])

    Time frame: On day of oocyte retrieval (up to 22 days after stimulation)

    The percentage of metaphase II oocytes to oocytes retrieved for participants where all oocytes were inseminated using ICSI will be presented.

  16. Fertilisation rate

    Time frame: On Day 1 after oocyte retrieval (up to 23 days after start of stimulation)

    The fertilisation rate is defined as the number of fertilized oocytes with 2 pronuclei divided by the number of oocytes retrieved.

  17. Number and quality of embryos on day 3 after oocyte retrieval

    Time frame: On Day 3 after oocyte retrieval (up to 25 days after start of stimulation)

    The total number of embryos and the number of good-quality embryos will be counted on Day 3. A good-quality embryo is defined as an embryo with ≥6 blastomeres and ≤20% fragmentation, without signs of multinucleation.

  18. Circulating concentrations of follicle-stimulating hormone (FSH) and luteinizing hormone (LH)

    Time frame: On stimulation day 6

    Blood samples for analysis of circulating concentrations of FSH and LH will be drawn.

  19. Circulating concentrations of estradiol

    Time frame: On stimulation day 6

    Blood samples for analysis of circulating concentrations of estradiol will be drawn.

  20. Circulating concentrations of progesterone

    Time frame: On stimulation day 6

    Blood samples for analysis of circulating concentrations of progesterone will be drawn.

  21. Circulating concentrations of inhibin A and inhibin B

    Time frame: On stimulation day 6

    Blood samples for analysis of circulating concentrations of inhibin A and inhibin B will be drawn.

  22. Circulating concentrations of FSH and LH

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    Blood samples for analysis of circulating concentrations of FSH and LH will be drawn.

  23. Circulating concentrations of estradiol

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    Blood samples for analysis of circulating concentrations of estradiol will be drawn.

  24. Circulating concentrations of progesterone

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    Blood samples for analysis of circulating concentrations of progesterone will be drawn.

  25. Circulating concentrations of inhibin A and inhibin B

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    Blood samples for analysis of circulating concentrations of inhibin A and inhibin B will be drawn.

  26. Total gonadotropin dose

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    The total gonadotropin dose will be recorded.

  27. Number of stimulation days

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  28. Proportion of subjects with investigator-requested gonadotropin dose adjustments

    Time frame: From stimulation Day 6 to end-of-stimulation (up to 20 stimulation days)

    The decreases and increases of the gonadotropin dose will be captured during the stimulation period.

  29. Number of events and intensity of adverse events

    Time frame: From signing of the informed consent up to end-of-trial (approximately 5.5 months)

  30. Changes from baseline in circulating levels of clinical chemistry parameters: Albumin and Total protein

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical chemistry parameters including: Albumin and Total protein.

  31. Changes from baseline in circulating levels of clinical chemistry parameters: Alanine transaminase, Alkaline phosphatase, Aspartate aminotransferase, Gamma-glutamyl transpeptidase

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical chemistry parameters including: Alanine transaminase, Alkaline phosphatase, Aspartate aminotransferase and Gamma-glutamyl transpeptidase.

  32. Changes from baseline in circulating levels of clinical chemistry parameters: Bicarbonate, Blood urea nitrogen, Calcium, Chloride, Cholesterol total, Glucose, Phosphorus, Potassium, Sodium, Uric acid

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical chemistry parameters including: Bicarbonate, Blood urea nitrogen, Calcium, Chloride, Cholesterol total, Glucose, Phosphorus, Potassium, Sodium and Uric acid.

  33. Changes from baseline in circulating levels of clinical chemistry parameters: Bilirubin direct, Bilirubin, Creatinine

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical chemistry parameters including: Bilirubin direct, Bilirubin and Creatinine.

  34. Changes from baseline in circulating levels of clinical chemistry parameters: Lactate dehydrogenase

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical chemistry parameter including: Lactate dehydrogenase.

  35. Proportion of subjects with markedly abnormal changes from baseline in clinical chemistry at end-of-stimulation

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) will be reported. The clinical chemistry parameters include: albumin, alanine transaminase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.

  36. Proportion of subjects with markedly abnormal changes from baseline in clinical chemistry at end-of-trial

    Time frame: At end-of-trial (up to approximately 5.5 months)

    Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) will be reported. The clinical chemistry parameters include: albumin, alanine transaminase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.

  37. Changes from baseline in circulating levels of clinical haematology parameters: Red blood cells, Red blood cells morphology

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical haematology including: Red blood cells and Red blood cell morphology.

  38. Changes from baseline in circulating levels of clinical haematology parameters: White blood cells, White blood cell morphology, Platelets

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical haematology including: White blood cells, White blood cell morphology and Platelets.

  39. Changes from baseline in circulating levels of clinical haematology parameters: Haemoglobin

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical haematology parameter including: Haemoglobin.

  40. Changes from baseline in circulating levels of clinical haematology parameters: Haematocrit

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical haematology parameter including: Haematocrit.

  41. Changes from baseline in circulating levels of clinical haematology parameters: Mean Corpuscular Volume

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical haematology parameter including: Mean Corpuscular Volume.

  42. Changes from baseline in circulating levels of clinical haematology parameters: Mean Corpuscular Haemoglobin

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical haematology parameter including: Mean Corpuscular Haemoglobin.

  43. Changes from baseline in circulating levels of clinical haematology parameters: Mean Corpuscular Hemoglobin Concentration

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

    Blood samples will be collected for the analysis of clinical haematology parameter including: Mean Corpuscular Hemoglobin Concentration.

  44. Proportion of subjects with markedly abnormal changes from baseline in haematology parameters at end-of-stimulation

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    Defined as number of participants with at least one markedly abnormal changes in haematology parameters (as assessed by investigator) will be reported. Haematology parameters include: red blood cells, red blood cell morphology, white blood cells, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.

  45. Proportion of subjects with markedly abnormal changes from baseline in haematology parameters end-of-trial

    Time frame: At end-of-trial (up to approximately 5.5 months)

    Defined as number of participants with at least one markedly abnormal changes in haematology parameters (as assessed by investigator) will be reported. Haematology parameters include: red blood cells, red blood cell morphology, white blood cells, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.

  46. Frequency of injection site reactions (redness, pain, itching, swelling and bruising)

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    Assessed by the participant during the stimulation period. Participants will self-assess injection site reactions (redness, pain, itching, swelling, and bruising) immediately, 30 minutes and 24 hours after each injection.

  47. Intensity of injection site reactions

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    Assessed by the participant during the stimulation period as mild, moderate or severe. Participants will be tabulated according to the highest severity of their reported injection site reactions.

  48. Frequency of immune-related adverse events

    Time frame: From signing of the informed consent up to end-of-trial (approximately 5.5 months)

    All adverse events reported in the trial will be analyzed to identify those that are potentially immune-related. They will be tabulated using the Standardised Medical Dictionary for Regulatory Activities [MedDRA] Queries (SMQs).

  49. Intensity of immune-related adverse events

    Time frame: From signing of the informed consent up to end-of-trial (approximately 5.5 months)

    Will be categorised as mild, moderate or severe.

  50. Proportion of subjects with cycle cancellations due to an adverse event, including immune-related adverse events, or due to technical malfunctions of the pre-filled injection pen

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    For each participant the reason for cycle cancellation will be recorded.

  51. Proportion of subjects with late OHSS (including OHSS of moderate/severe grade)

    Time frame: >9 days after triggering of final follicular maturation

    Late OHSS is defined as OHSS with onset >9 days after triggering of final follicular maturation. The proportion of participants with late OHSS, and late OHSS of moderate or severe grade will be presented.

  52. Proportion of subjects with OHSS (early and/or late) and/or preventive interventions for early OHSS

    Time frame: >9 days after triggering of final follicular maturation

    The proportion of participants with early and/or late OHSS and/or preventive interventions for early OHSS will be presented.

  53. Percentage of subjects with multi-fetal gestation, biochemical pregnancy, spontaneous abortion, ectopic pregnancy (with and without medical/surgical intervention) and vanishing twins

    Time frame: 10-11 weeks after transfer

    The percentage of participants with each of these events will be reported.

  54. Technical malfunctions of the pre-filled injection pen

    Time frame: At end-of-stimulation (up to 20 stimulation days)

    Participants will report any technical malfunctions of the pre-filled injection pen. Percentage of participants with confirmed technical malfunctions will be presented.

Sponsors and collaborators

Lead sponsor

Ferring Pharmaceuticals

Industry

Registry information

Official study title

A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial in India Comparing the Efficacy and Safety of FE 999049 (Follitropin Delta) With Follitropin Alfa (GONAL-F) in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme

Acronym: IRIS

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Feb 26, 2021
Registry last updated
Jan 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.